Bococizumab
Modify Date: 2025-10-29 14:08:56
Bococizumab structure
|
Common Name | Bococizumab | ||
|---|---|---|---|---|
| CAS Number | 1407495-02-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BococizumabBococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2]. |
| Name | Bococizumab |
|---|
| Description | Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PCSK9[1] |
| In Vivo | Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2]. Animal Model: Pregnant Sprague-Dawley (SD) rats[1] Dosage: 0, 10, 30, and 100 mg/kg Administration: Intravenous injection (i.v.) Result: Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters. |
| References |
| No Any Chemical & Physical Properties |